MacroGenics and NanoString Enter Translational Research Collaboration to Identify and Develop Biomarkers in Immuno-Oncology
PDF Version Translational Research Initiative Will Use PanCancer IO 360 Panel to Identify Predictive Signatures for MGD013 SEATTLE, Oct. 29, 2018 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that MacroGenics(NASDAQ:MGNX) and NanoString have entered into a translational research agreement to identify and develop biomarkers for MacroGenics’ MGD013 program.... Read more